文献速递白血病

维奈克拉联合改良强化化疗治疗老年急性髓系白血病试验(CAVEAT):维奈克拉联合改良强化化疗的Ib期剂量递增研究

Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.
PubMed 文献 · J Clin Oncol · 2020-07-20

这项Ib期剂量递增研究纳入51例适合强化化疗的老年急性髓系白血病患者,维奈克拉剂量范围50-600 mg,联合5+2方案(阿糖胞苷100 mg/m2第1-5天+伊达比星12 mg/m2第2-3天)诱导。未达到最大耐受剂量,诱导期主要≥3级非血液学毒性为发热性中性粒细胞减少(55%)和脓毒症(35%),总缓解率72%,原发AML为97%,继发AML为43%。

要点

  • 维奈克拉联合5+2诱导化疗在适合强化化疗的老年AML患者中安全可耐受,未达到最大耐受剂量(600 mg/天)。
  • 总缓解率(CR/CRi)为72%,原发AML为97%,继发AML为43%。
  • 巩固周期中血小板恢复明显延迟,与诱导期不同。

核心结论

  • 维奈克拉联合5+2诱导化疗在适合强化化疗的老年AML患者中安全且可耐受;尽管最佳缓解后治疗尚未确定,但原发AML的高缓解率值得进一步研究。

研究设计与样本

  • Ib期剂量递增研究,纳入51例年龄≥65岁(单体核型者≥60岁)且适合强化化疗的AML患者,维奈克拉剂量递增范围50-600 mg。
  • 维奈克拉每周期口服14天;诱导期先进行7天预治疗/剂量爬坡(第-6天至第0天),随后7天维奈克拉联合阿糖胞苷100 mg/m2第1-5天持续输注和伊达比星12 mg/m2第2-3天静脉注射(即5+2方案)。
  • 巩固治疗共4个周期,包括14天维奈克拉(第-6天至第7天)联合阿糖胞苷(第1-2天)和伊达比星(第1天);允许维奈克拉维持治疗(7个周期)。
  • 主要目的是评估维奈克拉联合5+2方案的最佳剂量方案。

主要发现

  • 患者中位年龄72岁(范围63-80岁),维奈克拉600 mg/天未达到最大耐受剂量。
  • 诱导期主要≥3级非血液学毒性为发热性中性粒细胞减少(55%)和脓毒症(35%)。
  • 与诱导期相比,巩固周期中血小板恢复明显延迟。
  • 总缓解率(完全缓解[CR]/血小板未完全恢复的CR)为72%;原发AML为97%,继发AML为43%。
  • 维奈克拉预治疗期间,NPM1、IDH2和SRSF2突变AML中观察到骨髓原始细胞减少≥50%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The B-cell lymphoma 2 (BCL-2) inhibitor venetoclax has an emerging role in acute myeloid leukemia (AML), with promising response rates in combination with hypomethylating agents or low-dose cytarabine in older patients. The tolerability and efficacy of venetoclax in combination with intensive chemotherapy in AML is unknown. PATIENTS AND METHODS: Patients with AML who were ≥ 65 years (≥ 60 years if monosomal karyotype) and fit for intensive chemotherapy were allocated to venetoclax dose-escalation cohorts (range, 50-600 mg). Venetoclax was administered orally for 14 days each cycle. During induction, a 7-day prephase/dose ramp-up (days -6 to 0) was followed by an additional 7 days of venetoclax combined with infusional cytarabine 100 mg/m2 on days 1-5 and idarubicin 12 mg/m2 intravenously on days 2-3 (ie, 5 + 2). Consolidation (4 cycles) included 14 days of venetoclax (days -6 to 7) combined with cytarabine (days 1-2) and idarubicin (day 1). Maintenance venetoclax was permitted (7 cycles). The primary objective was to assess the optimal dose schedule of venetoclax with 5 + 2. RESULTS: Fifty-one patients with a median age of 72 years (range, 63-80 years) were included. The maximum tolerated dose was not reached with venetoclax 600 mg/day. The main grade ≥ 3 nonhematologic toxicities during induction were febrile neutropenia (55%) and sepsis (35%). In contrast to induction, platelet recovery was notably delayed during consolidation cycles. The overall response rate (complete remission [CR]/CR with incomplete count recovery) was 72%; it was 97% in de novo AML and was 43% in secondary AML. During the venetoclax prephase, marrow blast reductions (≥ 50%) were noted in NPM1-, IDH2-, and SRSF2-mutant AML. CONCLUSION: Venetoclax combined with 5 + 2 induction chemotherapy was safe and tolerable in fit older patients with AML. Although the optimal postremission therapy remains to be determined, the high remission rate in de novo AML warrants additional investigation (ANZ Clinical Trial Registry No. ACTRN12616000445471).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Chua CC, Roberts AW, Reynolds J, et al. Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. J Clin Oncol. 2020. PMID: 32687450. doi:10.1200/JCO.20.00572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。